Automated, scaled, transposon-based production of CAR T cells

BACKGROUND: There is an increasing demand for chimeric antigen receptor (CAR) T cell products from patients and care givers. Here, we established an automated manufacturing process for CAR T cells on the CliniMACS Prodigy platform that is scaled to provide therapeutic doses and achieves gene-transfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lock, Dominik, Monjezi, Razieh, Brandes, Caroline, Bates, Stephan, Lennartz, Simon, Teppert, Karin, Gehrke, Leon, Karasakalidou-Seidt, Rafailla, Lukic, Teodora, Schmeer, Marco, Schleef, Martin, Werchau, Niels, Eyrich, Matthias, Assenmacher, Mario, Kaiser, Andrew, Prommersberger, Sabrina, Schaser, Thomas, Hudecek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472140/
https://www.ncbi.nlm.nih.gov/pubmed/36096530
http://dx.doi.org/10.1136/jitc-2022-005189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472140/
https://www.ncbi.nlm.nih.gov/pubmed/36096530
http://dx.doi.org/10.1136/jitc-2022-005189

Ejemplares similares